Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization
Kidney Failure
About this trial
This is an interventional prevention trial for Kidney Failure focused on measuring contrast induced nephropathy, contrast nephropathy, contrast media, kidney diseases, angiotensin converting enzyme inhibitors
Eligibility Criteria
Inclusion Criteria: Scheduled for Angiography in >= 24hrs from enrolment Documented Cr >= 150 within 3 months before cardiac catheterization AND/OR documented Cr >= 132umol/L within 1 week Before Cardiac Catheterization Currently Taking an ACE Inhibitor Exclusion Criteria: Patients with end stage renal disease (for example, patient on dialysis) Emergency Cardiac Catheterization with insufficient time to hold the ACEI Acute Pulmonary Edema
Sites / Locations
- Hamilton General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Hold ACEI or ARB
Continue ACE1 or ARB
Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
Randomized to continue on prescribed ACE1 or ARB